Frontiers | Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies
JAK Inhibitors: Prospects in Connective Tissue Diseases | SpringerLink
The emerging safety profile of JAK inhibitors in rheumatic disease | Nature Reviews Rheumatology
JAK Inhibitor I | CAS 457081-03-7 | SCBT - Santa Cruz Biotechnology
Frontiers | Emerging Topical and Systemic JAK Inhibitors in Dermatology
Phase 2 and 3 Trials of JAK Inhibitors For Atopic Dermatitis: A Review - Practical Dermatology
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases - ScienceDirect
Current and future status of JAK inhibitors - The Lancet
Selective inhibitors of JAK1 targeting a subtype-restricted allosteric cysteine - preLights
Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata | Actas Dermo-Sifiliográficas
Rheumatoid arthritis | JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis? | rheumatology.medicinematters.com
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases | Journal of Medicinal Chemistry
A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor | Journal of Medicinal Chemistry
Ruxolitinib | CAS 941678-49-5 | InvivoGen
JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases | SpringerLink
JAK inhibitors for the treatment of autoimmune and inflammatory diseases - ScienceDirect
JAK Inhibitors Are Coming and They Are the Biggest Eczema Development in Years | National Eczema Association
User's guide to JAK inhibitors in inflammatory bowel disease - ScienceDirect
Komplet remission ved behandling med JAK-hæmmer hos en patient med alopeciatotalis | Ugeskriftet.dk
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring | Dermatology and Therapy
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache? | SpringerLink
JAK inhibitors prevent JAK activation. The signaling cascade that... | Download Scientific Diagram
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib | Annals of the Rheumatic Diseases
Janus kinase 3 inhibitor - Wikipedia
